查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138364

全球口干药物市场-2022-2029

Global Xerostomia Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

口腔干燥症治疗市场的增长受到多种因素的推动，例如化疗使用的增加、意识的提高以及口腔干燥症和相关疾病的患病率上升。

口干症和相关疾病的日益流行正在增加对口干症治疗的需求并推动市场增长。

口干症和高血压、帕金森病、干燥综合征和糖尿病等相关疾病的发病率不断上升，对市场的增长产生了积极影响。糖尿病是口干的主要原因之一，当身体使用液体製造尿液时，其他东西的水就会减少，这发生在糖尿病中。因此，糖尿病会导致身体脱水和口干舌燥。口干会加剧糖尿病的副作用，提高血糖水平，并对您的身体造成严重破坏。特别是对于糖尿病患者来说，口干会导致经常蛀牙。这意味着当身体试图对抗感染时，血糖水平会上升。口干也会导致睡眠不足和味觉改变（口中有金属味或酸味）。

口干是老年人的常见病。研究表明，干燥综合征是大约 40% 的老年人口干的根本原因。干燥综合征是类风湿关节炎中第三常见的自身免疫性疾病。干燥综合征的人群患病率为 0.2%，每年每 100,000 人中有 4 例的发病率。干燥综合征在女性中的发病率是男性的 20 倍。干燥综合征会攻击製造眼泪和唾液的腺体，导致口干和眼睛干涩，并增加口干症病例。

高成本、药物的潜在副作用和严格的法规将成为全球口干症药物市场增长的不利因素。

现有的口干症治疗方法成本高、缺乏疗效和不常见的副作用，限制了全球口干症药物市场的增长。此外，美国食品和药物管理局 (FDA) 对药物批准的严格规定可能会阻碍市场增长。例如，以商品名Ethyol 销售的氨磷汀是唯一经美国FDA 验证可防止辐射引起的口干症的可用药物。

行业分析。

《全球口腔干燥症治疗药物市场报告》预计将根据波特五力、研发、流行病学、监管、定价和管道分析等各种行业因素对市场进行深入分析。 .

COVID-19 影响分析

由于在大流行期间实施了许多限制措施来限制 COVID-19 的传播，全球市场受到了负面影响，扰乱了供需链并减少了口腔干燥症治疗的销售。我是。此外，社会化法规使定期健康检查变得困难，导致大多数口干症患者未被发现，这对全球口干症药物市场产生了负面影响。

全球口腔干燥症治疗市场报告将提供对大约 40 多个市场数据表、45 多个数字和 200 多页（大约）的访问。

内容

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 口干症和相关疾病的病例增加
      • 研发进展
      • 市场策略
    • 限制因素
      • 药物的副作用
      • 严格的监管机构
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 流行病学分析
  • 研发
  • 管道分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 非处方药
  • 处方药

第 8 章按产品类型

  • 唾液分泌兴奋剂
  • 唾液替代品
  • 牙医
  • 人工唾液
  • 唾液腺笔

第 9 章按销售渠道

  • 医院药房
  • 零售药房
  • 在线药店

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • 第一三共公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • GlaxoSmithKline
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Acacia Pharma Group plc
  • Hikma Pharmaceuticals plc
  • Lupin Ltd.
  • Parnell Pharmaceuticals Inc.
  • Pendopharm, Virginia Head and Neck Therapeutics, Inc.
  • Pfizer Inc. and
  • Sun Pharmaceutical Industries Ltd

第13章 DataM

简介目录
Product Code: DMPH2168

Market Overview

Xerostomia Therapeutics Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 3.8% during the forecast period (2022-2029).

Xerostomia is defined as dry mouth resulting from reduced or absent saliva flow. Xerostomia is not a disease but is a symptom of toxicity from chemotherapy, head and neck radiotherapy, adverse effects of medications, autoimmune disease, or other conditions such as uncontrolled diabetes, infections, and hormonal changes. Xerostomia occurs commonly in those with Sjogren disease or who are receiving radiation therapy for head and neck cancer. Xerostomia is a common complaint among older adults, affecting approximately 20% of the elderly. Reduced salivary flow can cause difficulties in tasting, chewing, swallowing, and speaking; it can also increase the chance of developing dental decay, demineralizing teeth, tooth sensitivity, and oral infections.

Market Dynamics

The xerostomia therapeutics market growth is driven by several factors, such as an increase in chemotherapy, growing awareness and rising prevalence of xerostomia and associated diseases.

The growing prevalence of xerostomia and associated diseases has increased the demand for xerostomia therapeutics fueling the market growth.

The growing occurrence of xerostomia and related diseases such as hypertension, Parkinson's disorder, Sjogren's syndrome and diabetes positively impact market growth. Diabetes is one of the major causes that causes of dry mouth; there is less moisture for other things when the body is using fluids to make urine, which happens in diabetes. Diabetes hence leads to a dehydrated body and mouth that feels dry. Xerostomia can exacerbate the side effects of diabetes, increasing glucose levels and wreaking havoc on the body. Having xerostomia, especially as a diabetes patient, can lead to rampant tooth decay, which means blood sugar increases as the body tries to fight infection. A dry mouth can also lead to loss of sleep and an altered sense of taste, a condition that presents a metallic or sour taste in the mouth.

Xerostomia is a common symptom in the elderly population. Studies have suggested that the underlying cause of approximately 40% of xerostomia in the elderly is Sjogren's syndrome. Sjogren's syndrome is the third most common rheumatic autoimmune disorder. The population prevalence of Sjogren's syndrome is 0.2%, with an incidence of 4 cases per 100,000 per year. Sjogren's is 20 times more common in females than males. Sjogren's syndrome attacks the glands that make tears and saliva; this causes a dry mouth and dry eyes, increasing the cases of xerostomia.

The high cost, chances of drug side effects and stringent regulations will be the demoting reasons for the global xerostomia therapeutics market growth.

The High cost, ineffectiveness and common and uncommon side effects of available treatments for xerostomia are restraining the growth of the global xerostomia therapeutics market. In addition, stringent U.S. Food and Drug Administration (FDA) regulations for drug approval can hamper market growth. For instance, Amifostine-sold under the trade name Ethyol is the only drug available validated by the U.S FDA for protecting radiation-induced xerostomia.

Industry analysis.

The global xerostomia therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, and pipeline analysis.

COVID-19 Impact Analysis

In the pandemic, the global market was negatively affected as many restrictions were imposed to limit the COVID-19 spread, which led to the disruption of the supply and demand chain, reducing the sales of the Xerostomia therapeutics. Furthermore, the socializing restriction made it difficult to get regular healthcare checkups, leaving most Xerostomia patients undetected, negatively impacting the global Xerostomia therapeutics market.

Segment Analysis

Salivary stimulants are presumed to be prevailing throughout the forecast period (2022-2029)

Salivary stimulants are expected to be the largest market shareholder over the period forecast (2022-2029). Topical salivary stimulant flow products include over-the-counter sugar-free gums, mints, and candies. Salivary stimulants include the sialagogues pilocarpine hydrochloride (Salagen®) and cevimeline hydrochloride (Evoxac®). Pilocarpine and cevimeline bind to muscarinic receptors, stimulating exocrine gland activity (such as salivary and sweat glands) and increasing smooth muscle tone in the gastrointestinal and urinary tracts. Common adverse effects include sweating, headache, GI discomfort, nausea, increased lacrimation, urinary frequency, and palpitations. Sialogogic drugs are substances designed to stimulate salivary secretion as they affect the systemic pathway. Using sugar-free chewing gum or tablet can increase salivary secretion and improve the sensation of dry mouth with gustatory and masticatory stimulation. These products include fluoride, chlorhexidine, calcium phosphate, and xylitol releasers. Salivary stimulants are highly popular as they are readily available and can be taken without adverse effects.

Geographical Analysis

The North American region is overshadowing the global xerostomia therapeutics market.

North America was dominating the xerostomia therapeutics market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase in cancer and xerostomia-associated disorders such as Sjogren's disorder, a highly aware population, advanced healthcare infrastructure, favorable government initiatives and growth in research and development. As per the National Cancer Institute, in 2020, around 1,806,590 new cancer cases were diagnosed in the US, and 606,520 people died. These numbers increase yearly, along with the causes such as lifestyle changes, smoking, etc. The US is very advanced in healthcare, and the population is generally aware; this leads to growing chemotherapy treatment cases leading to xerostomia.

Similarly, other diseases associated with xerostomia, such as Parkinson's and Sjogren's syndrome, are also on the rise in the region; Sjogren's occurs in 0.1 to 1 percent of the population and is one of the most prevalent autoimmune diseases. Nine out of 10 patients are women. Initiatives launched by various organizations, such as the "5-year breakthrough goal" by Sjogren's Syndrome Foundation, focus on faster diagnosis and better treatment.

Competitive Landscape

Some of the major key players in the market are GlaxoSmithKline, Church & Dwight Co., Inc., Colgate-Palmolive Company, Acacia Pharma Group plc, Hikma Pharmaceuticals plc, Lupin Ltd., Parnell Pharmaceuticals Inc., Pendopharm, Virginia Head and Neck Therapeutics, Inc., Pfizer Inc. and Sun Pharmaceutical Industries Ltd. In the xerostomia therapeutics market, GlaxoSmithKline will dominate the market, owning to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, contributing to the growth of the global xerostomia therapeutics market. For instance, on February 11, 2021, Virginia Head and Neck Therapeutics, Inc. introduced the Voutia device, which provides continuous relief from xerostomia.

Daiichi Sankyo Company

Overview

Daiichi Sankyo Company, Limited is a leading global pharmaceutical company and is the second-largest pharmaceutical company in Japan. As of March 2020, it has 15,348 employees. Daiichi Sankyo Company was founded in 2005 and is headquartered in Tokyo, Japan.

Product Portfolio

Daiichi Sankyo Company's xerostomia product portfolio has Evoxac.

The global xerostomia therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Cases Growing Prevalence of Xerostomia And Associated Diseases
      • 4.1.1.2. Research and Development
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Drug Side Effects
      • 4.1.2.2. Stringent Regulatory Bodies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiological Analysis
  • 5.3. Research and Developments
  • 5.4. Pipeline Analysis
  • 5.5. Supply Chain Analysis
  • 5.6. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. OTC
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Prescription

8. By Product Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 8.1.2. Market Attractiveness Index, By Product Type Segment
  • 8.2. Salivary Stimulants
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Salivary Substitutes
  • 8.4. Dentifrices
  • 8.5. Artificial Saliva
  • 8.6. Salivary Pen

9. By Distribution Channels

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channels Segment
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Daiichi Sankyo Company
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline
  • 12.3. Church & Dwight Co., Inc.
  • 12.4. Colgate-Palmolive Company
  • 12.5. Acacia Pharma Group plc
  • 12.6. Hikma Pharmaceuticals plc
  • 12.7. Lupin Ltd.
  • 12.8. Parnell Pharmaceuticals Inc.
  • 12.9. Pendopharm, Virginia Head and Neck Therapeutics, Inc.
  • 12.10. Pfizer Inc. and
  • 12.11. Sun Pharmaceutical Industries Ltd

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact